Company

History

BREONICS is a private research and discovery company located in Albany, New York. Organized in 1996, the company has developed a new and innovative technology Exsanguinous Metabolic Support (EMS) which enables the continued oxidative metabolism and function of organs and tissues while isolated from the rest of the human body. EMS is the first technology that can be used to intervene after cardiac arrest and repair ischemically damaged kidneys for transplantation. This unique ability of EMS changes today’s limitation of recovering cadaveric kidneys from within minutes of death to a window of several hours postmortem. Resulting in significant broadening the criteria for organ donation to include those patients who are declared dead from cardiac arrest at an accident scene, in the ER, or in the hospital.

Investor Relations

BREONICS is currently a privately-held company. For more information please contact breonicsinvest@breonics.com

Business Development

BREONICS intends to form strategic alliances with companies that have the late stage development and commercial infrastructure to bring medical products to market. BREONICS particular interest is forging a synergistic relationship with a corporate partner that will provide a conduit for BREONICS other applications.

Career Opportunities

At BREONICS, our people drive the innovation that is translational to the clinic. If you are interested in joining a growing company that is tackling some of the biggest issues in medicine today, we’d like to hear from you. The company will be filling positions in the lab, clinic and management over the next two years. Please reach out to our team in the “contact us” section if you’d like to be considered as positions become available.